Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalitinib in mCRPC With Soft Tissue or Visceral Metastases
NCT07608718Phase 2Not yet recruiting
- Start
- Oct 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in metastatic castration-resistant prostate cancer (mCRPC). Primary endpoint: Radiographic Progression Free Survival at 6 months. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07608718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07608718.